Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Apr 12, 2024 11:21am
71 Views
Post# 35985743

RE:RE:Quentin30 is a pathological prevaricator.

RE:RE:Quentin30 is a pathological prevaricator.If Quentin30 now claims to have worked in the biotech industry ( and now is trying to give the impression that he works for a brokerage company), then his experience is considerably narrow and limited to past - when practicaly nothing that he talks about is happening today. Everything has changed including federal regulations, FDA interactions with sponsor companies, fast track and breakthrough approval processes - with the recent introduction of accelerated approval, the influence of the inflation reduction act (IRA) in providing market exclusivity aside form the patent system, the rising prominence of biologics, the rise of immunotherapeutics and their combintions, a focus on Orphan/Rare diseases over common diseases, etc. etc. 
<< Previous
Bullboard Posts
Next >>